Great occipital nerve long-acting steroid injections in cluster headache therapy: an observational prospective study.
Cluster headache
Great occipital nerve
Methylprednisolone
Transitional therapy
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
16
09
2021
accepted:
01
11
2021
revised:
30
10
2021
pubmed:
26
11
2021
medline:
25
3
2022
entrez:
25
11
2021
Statut:
ppublish
Résumé
Injections targeting the occipital nerve are used to reduce headache attacks and abort cluster bouts in cluster headache patients. There is no widely accepted agreement over the optimal technique of injection, type and doses of steroids and/or anesthetics to use, as well as injection regimens. The aim of this study was to verify the effectiveness and safety of greater occipital nerve long-acting steroid injections in the management of episodic and chronic cluster headache. We conducted a prospective observational cohort study on episodic (ECH) and chronic cluster headache patients (CCH). ECH were included in the study at the beginning of a cluster period. Three injections with 60 mg methylprednisolone were performed on alternate days. We registered the frequency and intensity of attacks three days before and 3, 7 and 30 days after the treatment, the latency of cluster relapse, adverse events, scores evaluating anxiety (Zung scale), depression (Beck's Depression Scale) and quality of life (Disability Assessment Schedule II, 12-Item Self-Administered Version). Primary outcome was the interruption of the cluster after the three injections. Responders conducted a follow-up period of 12 months. We enrolled 60 patients, 47 with ECH and 13 with CCH. We observed a complete response in 47.8% (22/46) of episodic and 33.3% (4/12) of chronic patients. Moreover, a partial response (reduction of at least 50% of attacks) was obtained in further 10.8% (5/46) of episodic and in 33.3% (4/12) of chronic patients at 1 month. Median pain-free period was of 3 months for CCH responders. Only mild adverse events were reported in 38.3% (23/58) cases. We suggest three greater occipital nerve injections of 60 mg methylprednisolone on alternate days as useful therapy in episodic and chronic cluster headache. This leads to a long pain-free period in chronic forms. Adverse effects are mild and support its use as first choice. The study was inserted in AIFA observational studies register.
Sections du résumé
BACKGROUND
BACKGROUND
Injections targeting the occipital nerve are used to reduce headache attacks and abort cluster bouts in cluster headache patients. There is no widely accepted agreement over the optimal technique of injection, type and doses of steroids and/or anesthetics to use, as well as injection regimens. The aim of this study was to verify the effectiveness and safety of greater occipital nerve long-acting steroid injections in the management of episodic and chronic cluster headache.
METHODS
METHODS
We conducted a prospective observational cohort study on episodic (ECH) and chronic cluster headache patients (CCH). ECH were included in the study at the beginning of a cluster period. Three injections with 60 mg methylprednisolone were performed on alternate days. We registered the frequency and intensity of attacks three days before and 3, 7 and 30 days after the treatment, the latency of cluster relapse, adverse events, scores evaluating anxiety (Zung scale), depression (Beck's Depression Scale) and quality of life (Disability Assessment Schedule II, 12-Item Self-Administered Version). Primary outcome was the interruption of the cluster after the three injections. Responders conducted a follow-up period of 12 months.
RESULTS
RESULTS
We enrolled 60 patients, 47 with ECH and 13 with CCH. We observed a complete response in 47.8% (22/46) of episodic and 33.3% (4/12) of chronic patients. Moreover, a partial response (reduction of at least 50% of attacks) was obtained in further 10.8% (5/46) of episodic and in 33.3% (4/12) of chronic patients at 1 month. Median pain-free period was of 3 months for CCH responders. Only mild adverse events were reported in 38.3% (23/58) cases.
CONCLUSIONS
CONCLUSIONS
We suggest three greater occipital nerve injections of 60 mg methylprednisolone on alternate days as useful therapy in episodic and chronic cluster headache. This leads to a long pain-free period in chronic forms. Adverse effects are mild and support its use as first choice.
TRIAL REGISTRATION
BACKGROUND
The study was inserted in AIFA observational studies register.
Identifiants
pubmed: 34820736
doi: 10.1007/s00415-021-10884-0
pii: 10.1007/s00415-021-10884-0
pmc: PMC8940833
doi:
Substances chimiques
Steroids
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2193-2199Informations de copyright
© 2021. The Author(s).
Références
Cephalalgia. 2012 Jun;32(8):630-4
pubmed: 22623755
Eur J Neurol. 2014 Feb;21(2):338-43
pubmed: 24313966
Clin Anat. 2006 May;19(4):332-6
pubmed: 16258972
Cephalalgia. 2017 Aug;37(9):873-880
pubmed: 27313215
Cephalalgia. 2002 Sep;22(7):520-2
pubmed: 12230593
Rev Neurol (Paris). 1989;145(2):160-2
pubmed: 2727541
Psychosomatics. 1971 Nov-Dec;12(6):371-9
pubmed: 5172928
Lancet Neurol. 2011 Oct;10(10):891-7
pubmed: 21903477
Headache. 2016 Jul;56(7):1093-106
pubmed: 27432623
J Neurosurg. 1961 Sep;18:605-9
pubmed: 13752671
Expert Rev Neurother. 2020 Nov;20(11):1157-1167
pubmed: 32781922
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Cephalalgia. 2003 Sep;23(7):504-10
pubmed: 12950375
Headache. 2019 Jan;59(1):56-62
pubmed: 30144049
J Clin Neurosci. 2019 Oct;68:140-145
pubmed: 31326284
Pain. 2006 May;122(1-2):126-9
pubmed: 16527404
Pain. 2005 Nov;118(1-2):92-6
pubmed: 16202532